Fibronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy
Authors:
- Lauro Thiago TuraçaLTLauro Thiago Turaça
- João Bosco PesqueroJPJoão Bosco Pesquero
- Gregory MennecierGMGregory Mennecier
- Maria Lucia Zaidan DagliMaria Lucia Zaidan Dagli
- Roger ChammasRCRoger Chammas
- Nestor SchorNSNestor Schor
- Maria Helena BelliniMBMaria Helena Bellini
- 1 September 2012
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 66 (6) , 464-468
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Surgical Treatment of Renal Cell Cancer Liver Metastases: A Population-Based StudyAnnals of Surgical Oncology, 2011
- Tumor Biology and Prognostic Factors in Renal Cell CarcinomaThe Oncologist, 2011
- Imaging of Renal Cell Carcinoma: State of the Art and Recent AdvancesUrologia Internationalis, 2010
- Targeted therapies in renal cell cancer: recent developments in imagingTargeted Oncology, 2010
- Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell CarcinomasPLOS ONE, 2010
- Integrins in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2010
- Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy EraEuropean Urology, 2009
- Recent advances in the treatment of renal cell carcinoma and the role of targeted therapiesEuropean Journal of Cancer, 2008
- Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL -mutant renal carcinoma cellsCarcinogenesis, 2008
- Interleukin-2: Clinical applicationsSeminars in Oncology, 2002